// App-Quantinova.ai

P217 : Efficacy and safety of filgotinib for patients with RA naïve to MTX therapy: FINCH3 primary outcome results

Researchers

Presenter

  • Neil McKay

Principal Investigators

  • Dsire van der Heijde

  • Rene Westhovens

  • William F. C Rigby

  • Daniel W. T Ching

  • Beatrix Bartok

  • Franziska Matzkies

  • Zhaoyu Yin

  • Ying Guo

  • Chantal Tasset

  • John S Sundy

  • Neelufar Mozaffarian

  • Osvaldo D Messina

  • Robert B. M Landew

  • Tatsuya Atsumi

  • Gerd R Burmester

Medical Centers

  • Clinical Rheumatology, Western General Hospital, Edinburgh, UNITED KINGDOM

  • Rheumatology, Leiden University Medical Centre, Leiden, NETHERLANDS

  • Rheumatology, University Hospitals Leuven, Leuven, BELGIUM

  • Medicine, Dartmouth College USA, Hanover, CT

  • Rheumatology, Timaru Hospital, Timaru, NEW ZEALAND

  • Epidemiology, Gilead Sciences, Foster City, CA

  • Inflammation, Gilead Sciences, Foster City, CA, USA

  • Biostatistics, Gilead Sciences, Inc, Foster City, CA

  • Rheumatology, Galapagos NV, Mechelen, BELGIUM

  • Rheumatology, Cosme Argerich Hospital and IRO Medical Center, Buenos Aires, ARGENTINA

  • Rheumatology, Amsterdam University Medical Center, Amsterdam, NETHERLANDS

  • Rheumatology, Hokkaido University, Sapporo, JAPAN

  • Rheumatology, Charité-University Medicine Berlin, Berlin, GERMANY

Locations

  • United Kingdom

  • Netherlands

  • Belgium

  • United States

  • New Zealand

  • Argentina

  • Japan

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Filgotinib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved